Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice

Journal of Clinical Investigation

Volumn 102, Issue 5, 1998, Pages 910-918

  Nicoletti, Antonino ^a,b   Kaveri, Srini ^b   Caligiuri, Giuseppina ^a   Bariéty, Jean ^b   Hansson, Göran K ^a,c  

^a Karolinka Institute   (Sweden)

^b INSERM   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibody; Atherosclerosis; Immunoglobulin; T cells

Indexed keywords

APOLIPOPROTEIN E; IMMUNOGLOBULIN; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE;

EID: 0032168737     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119892     Document Type: Article

References (32)

1. Stemme, S., B. Faber, J. Holm, O. Wiklund, J.L. Wiuum, and G.K. Hansson. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 92:3893-3897.
2. Palinski, W., M.E. Rosenfeld, S. Yla-Herttuala, G.C. Gunner, S.S. Socher, S.W. Butler, S. Parthasarathy, T.E. Carcw, D. Steinberg, and J.L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1372-1376.
3. Ylä-Herttuala, S., W. Palinski, M.E. Rosenfeld. S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1086-1095.
4. Seifert,. P.S., and O.K. Hansson. 1989. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 9:802-811.
5. Seifert, P.S., F. Hugo, G.K. Hansson, and S. Bhakdi. 1989. Prelesional complement activation in experimental atherosclerosis: terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab. Invest. 60:747-754.
6. Salonen, J.T., S. Ylä-Herttuala. R. Yamamoto, S. Butler. H. Korpela, R. Salonen, K. Nyyssänen, W. Palinski, and J.L. Witztum. 1992. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339: 883-887.
7. Plump, A.S., J.D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
8. Zhou, X., S. Stemme, and G.K. Hansson. 1996. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 149:359-366.
9. Palinskim, W., V.A. Ord, A.S. Plump, J.L. Breslow, D. Steinberg, and J.L. Witztum. 1994. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:605-616.
10. Smith, J.D., E. Trogan, M. Ginsberg, C. Grigaux, J. Tian, and M. Miyata. 1995. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Nait. Acad. Sci. USA. 92:8264-8268.
11. Dansky, H.M., S.A. Charlton, M.M. Harper, and J.D. Smith. 1997. T and B lymphocytes play a minor role in atherosclerosis plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 94:4642-4646.
12. Gupta, S., A.M. Pablo, X.C. Jiang, N. Wang, and C. Schindler. 1997. IFN-γ potentiates atherosclerosis in apo E knock-out mice. J. Clin. Invest. 99: 2752-2761.
13. Dwyer, J.M. 1992. Manipulating the immune system with immune globulin. N. Engl. J. Med. 326:107-116.
14. Kaveri, S.V., G. Dietrich, V. Hurez, and M.D. Kazatchkine. 1991. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin. Exp. Immunol. 86:192-198.
15. Kazatchkine, M.D., G. Dietrich, V. Hurez, N. Ronda, B. Bellon, F. Rossi, and S.V. Kaveri. 1994. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol. Rev. 139:79-107.
16. Rossi, F., B. Bellon, M.C. Vial. P. Druet, and M.D. Kazatchkine. 1991. Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride-induced autoimmune disease of Brown-Norway rats. Clin. Exp. Immunol. 84:129-133.
17. Forsgren, S., A. Andersson, V. Hillorn, A. Soderstrom, and D. Holmberg. 1991. Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Scand. J. Immunol. 34:445-451.
18. 1 mice. Eur. J. Immunol. 24:8-15.
19. Saoudi, A., V. Hurez, Y. de Kozak, J. Kuhn. S.V. Kaveri. M.D. Kazatchkine, P. Druet, and B. Bellon. 1993. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int. Immunol. 5:1559-1567.
20. Piedrahita, J.A., S.H. Zhang, J.R. Hagaman, P.M. Oliver, and N. Maeda. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89:4471-4475.
21. Palinski, W., S. Ylä-Herttuala. M.E. Rosenfeld. S.W. Butler. S.A. Socher, S. Parthasarathy, L.K. Curtiss, and J.L. Witztum. 1990. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 10:325-335.
22. Steinbrecher, U.P. 1987. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262:3603-3608.
23. Nakashima, Y., A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:133-140.
24. Andersson, U., L. Björk. U. Skansén-Sitphir, and J. Andersson. 1994. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol. Rev: 139:21-42.
25. Shi, C., W.S. Lee, Q. He, D. Zhang, D.L. Fletcher, Jr., J.B. Newell, and E. Haber. 1996. Immunologic basis of transplant-associated arteriosclerosis. Proc. Natl. Acad. Sci. USA. 93:4051-4056.
26. Sohma, Y., H. Sasano, R. Shiga, S. Saeki, T Suzuki, H. Nagura, M. Nose, and T. Yamamolo. 1995. Accumulation ot plasma cells in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA. 92:4937-4941.
27. Hurez, V., S.V. Kaveri, B.A. Mouhou, G. Dietrich, J.C. Mani, D. Klatzmann, and M.D. Kazatchkine. 1994. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin. IVIg). Therap. lmmunul. 1:269-278.
28. Kaveri, S., T. Vassilev, V. Hurez, R. Lengagne, S. Cot. P. Pouletty, and D. Glotz. 1996. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg).J. Clin. Invest. 97:865-869.
29. Takei, S., Y. Arora, and S.M. Walker. 1993. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J. Clin. Invest. 91:602-607.
30. Vassilev, T., C. Gelin, S.V. Kavcri, M.T. Zilber, L. Boumsell, and M.D. Kazatchkine. 1993. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins. IVIg). Clin. Exp. Immunol. 92:364-372.
31. Lam, L., C.F. Whitsett, J.M. McNicholl, T.W. Hodge, and J. Hooper. 1993. Immunologically active proteins in intravenous immunoglobulin. Lancet. 342:678.
32. Blasczyk, R., U. Westhoff, and H. Grossewilde. 1993. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 341:789-740.